BMS, Mirati fund new Stand Up To Cancer research teams, adding to list of pharma partnerships
Stand Up To Cancer is well-known for its celebrity connections and gala fundraising events, but in pharma and biotech, it’s also known as a research partner. Its two recently added teams partner with Bristol Myers Squibb on lung cancer disparities and Mirati Therapeutics on KRAS cancers.
The new additions augment Stand Up To Cancer’s pharma partnerships, which include 13 teams in its Catalyst program. The Catalyst program launched in 2016, sponsored initially by BMS, Merck and Roche’s Genentech, to pair industry funding and materials with scientific partners with the ambition to accelerate cancer research, detection and treatment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.